Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorPernas, Sonia
dc.contributor.authorVillagrasa, Patricia
dc.contributor.authorVivancos Prellezo, Ana
dc.contributor.authorScaltriti, Maurizio
dc.contributor.authorRodon Ahnert, Jordi
dc.contributor.authorBurgués, Octavio
dc.contributor.authorNuciforo, Paolo Giovanni
dc.contributor.authorAntunes de Melo Oliveira, Ana Mafalda
dc.date.accessioned2022-05-13T06:46:13Z
dc.date.available2022-05-13T06:46:13Z
dc.date.issued2021-11-04
dc.identifier.citationPernas S, Villagrasa P, Vivancos A, Scaltriti M, Rodón J, Burgués O, et al. First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study. Front Oncol. 2021 Nov 4;11:744112.
dc.identifier.issn2234-943X
dc.identifier.urihttps://hdl.handle.net/11351/7527
dc.descriptionAnàlisi de seqüències d'ADN; Subtipus PAM50; Genètica molecular
dc.description.sponsorshipThis study was supported by a grant from Novartis. This study was funded, in part, by the project PI 15/01508, integrated in the Plan Estatal I+D+I and co-funded by Instituto de Salud Carlos III - Subdirección General de Evaluación and European Regional Development Fund (ERDF) (to EC) and by a grant from Mutua Madrileña Foundation (to EC). The decisions and responsibilities of this study were all under the sponsor: SOLTI Breast Cancer Research Group.
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.ispartofseriesFrontiers in Oncology;11
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectMama - Càncer - Tractament
dc.subjectMama - Càncer - Aspectes moleculars
dc.subjectFarmacologia molecular
dc.subject.meshMolecular Targeted Therapy
dc.subject.meshBreast Neoplasms
dc.subject.meshGenomics
dc.titleFirst Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3389/fonc.2021.744112
dc.subject.decsterapia molecular selectiva
dc.subject.decsneoplasias de la mama
dc.subject.decsgenómica
dc.relation.publishversionhttps://doi.org/10.3389/fonc.2021.744112
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Pernas S] Catalan Institute of Oncology (ICO)- Institut d’Investigació Biomédica de Bellvitge (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain. [Villagrasa P] SOLTI Breast Cancer Research Group, Barcelona, Spain. [Vivancos A] Cancer Genomics Laboratory, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Scaltriti M] Memorial Sloan Kettering Cancer Center, Memorial Hospital, New York, NY, United States. [Rodón J] Oncology Department, Monroe Dunaway (MD) Anderson Cancer Center, Houston, TX, United States. Servei d’Oncologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Burgués O] Pathology Department, Hospital Clínico Universitario Valencia, Valencia, Spain. [Nuciforo P] Molecular Oncology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Oliveira M] SOLTI Breast Cancer Research Group, Barcelona, Spain. Servei d’Oncologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid34804931
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail
Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple